Thermo Fisher Scientific Inc. (NYSE:TMO) is a prominent player in the medical instruments industry, known for its innovative solutions in scientific research, healthcare, and diagnostics. The company is set to release its quarterly earnings on January 30, 2025, with Wall Street analysts estimating an earnings per share (EPS) of $5.94 and projected revenue of approximately $11.28 billion.
Thermo Fisher's anticipated year-over-year earnings increase is driven by higher revenues for the quarter ending December 2024. The Zacks Consensus Estimate projects revenues of $11.25 billion, reflecting a 3.3% increase from the same quarter last year. The earnings per share are expected to be $5.92, marking a 4.4% growth from the previous year's figures.
The company's strong performance is likely supported by its Analytical Instruments and Specialty Diagnostics segments. In the previous quarter, Thermo Fisher's earnings per share were $5.28, surpassing the Zacks Consensus Estimate by 0.6%. Over the past four quarters, the company has consistently exceeded earnings expectations, with an average surprise of 3.63%.
Thermo Fisher's consistent track record of surpassing earnings estimates positions it as a promising candidate for continuing this trend. In the last reported quarter, the company achieved earnings of $5.28 per share, exceeding the Zacks Consensus Estimate of $5.25 per share, marking a surprise of 0.57%. This consistent performance suggests that Thermo Fisher is well-positioned to potentially beat estimates once again.
The company's financial metrics indicate a strong market valuation. With a price-to-earnings (P/E) ratio of approximately 36.38 and a price-to-sales ratio of about 5.27, Thermo Fisher reflects a robust market valuation. The debt-to-equity ratio of 0.72 shows a moderate level of debt compared to equity, while a current ratio of 1.63 suggests good liquidity to cover short-term liabilities.
Read More